Novo Nordisk has released phase 2 clinical trial results for Amycretin, potentially a successor to its successful drugs Wegovy and Ozempic. The trials...

Novo Nordisk jumps after phase II data show amycretin offers significant weight loss and HbA1c level reductions in type 2 diabetes patients.

Novo Nordisk jumps after phase II data show amycretin offers significant weight loss and HbA1c level reductions in type 2 diabetes patients.

Bagsværd, Denmark, 25 November 2025 – Novo Nordisk today announced positive headline results from a phase 2 clinical trial with amycretin...

Oral semaglutide—the ingredient in obesity and diabetes drugs Ozempic and Wegovy—didn’t slow Alzheimer’s disease in two...

Oral semaglutide—the ingredient in obesity and diabetes drugs Ozempic and Wegovy—didn’t slow Alzheimer’s disease in two...

New research is shedding light on how weight-loss and diabetes medications like Ozempic, Wegovy, and Mounjaro affect not only appetite but also the...

New research is shedding light on how weight-loss and diabetes medications like Ozempic, Wegovy, and Mounjaro affect not only appetite but also the...

A new oral GLP-1 medication can help adults with obesity and Type 2 diabetes lose more weight and improve their blood sugar levels compared to a...

Public interest in GLP‑1 receptor agonists has exploded in recent years. These medicines, known as GLP‑1 RAs, include drugs like semaglutide,...